Desh Rakshak

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE971E01016
  • NSEID:
  • BSEID: 531521
INR
23.16
0.00 (0.00%)
BSENSE

Mar 04

BSE+NSE Vol: 800

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

800 (300.00%) Volume

Shareholding (Dec 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

50.03%

What does Desh Rakshak do?

06-Jun-2025

Desh Rakshak Aushdhalaya Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, focusing on Ayurvedic and herbal products. As of March 2025, it reported net sales of 4 Cr and a market cap of Rs 17 Cr.

Overview:<BR>Desh Rakshak Aushdhalaya Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, specializing in the manufacture of pure Ayurvedic and herbal products.<BR><BR>History:<BR>The company was originally established in 1901 as a proprietorship by Shri Bhagwant Rai Jain and was converted into a Private Limited Company in July 1994. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 17 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 17.00 <BR>Industry P/E: 27 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.34 <BR>Return on Equity: 5.37% <BR>Price to Book: 1.78 <BR><BR>Contact Details:<BR>Address: Bhagwant Kuti, Kankhal Haridwar UTT : 249408 <BR>Phone: 91-1334-243833 <BR>Email: daral96@yahoo.in/dral95@yahoo.com <BR>Website: http://www.deshrakshak.com

View full answer

Has Desh Rakshak declared dividend?

06-Jun-2025

No Dividend History Available

What is the technical trend for Desh Rakshak?

09-Jun-2025

As of May 29, 2025, Desh Rakshak's technical trend is mildly bullish, supported by bullish MACD and moving averages, despite some bearish signals from the RSI and KST.

As of 29 May 2025, the technical trend for Desh Rakshak has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. However, the weekly RSI is bearish, suggesting some weakness in the short term. Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames, supporting the overall mildly bullish trend. Daily moving averages are bullish, reinforcing the positive outlook. The KST indicates a mildly bearish trend on the weekly, but bullish on the monthly, which adds mixed signals. Dow Theory shows a mildly bearish trend on the weekly, with no trend on the monthly. Overall, the technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some bearish signals from the RSI and KST.

View full answer

Who are the peers of the Desh Rakshak?

16-Jul-2025

Peers of Desh Rakshak include Genesis IBRC, Vineet Laborator, Ishita Drugs, Phaarmasia, Zenith Health, Colinz Labs, Checkpoint Trend, Chemo Pharma Lab, and Parmax Pharma. Desh Rakshak has the highest 1-year return at 415.29%, while most peers exhibit Below Average management risk and growth, with Vineet Laborator showing the lowest return at -49.62%.

Peers: The peers of Desh Rakshak are Genesis IBRC, Vineet Laborator, Ishita Drugs, Phaarmasia, Zenith Health, Colinz Labs, Checkpoint Trend, Chemo Pharma Lab, and Parmax Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at none, while Average management risk is found at Vineet Laborator, and the rest have Below Average management risk. Growth is Below Average for Vineet Laborator, Ishita Drugs, Phaarmasia, Zenith Health, Colinz Labs, Checkpoint Trend, and Parmax Pharma, while Desh Rakshak also falls into the Below Average category. Capital Structure shows Good ratings at Ishita Drugs, Zenith Health, and Colinz Labs, while the rest, including Desh Rakshak, have Below Average ratings.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Desh Rakshak at 415.29%, while the lowest is Vineet Laborator at -49.62%, indicating that Desh Rakshak significantly outperforms its peers. Additionally, Phaarmasia, Zenith Health, Colinz Labs, and Parmax Pharma all have negative six-month returns.

View full answer

Who are in the management team of Desh Rakshak?

16-Jul-2025

As of March 2022, the management team of Desh Rakshak includes Tosh Kumar Jain (Chairman & Managing Director), Monika Jain and Arihant Kumar Jain (Whole-time Directors), Mohit Kumar (Independent Director), Sohini Bansal (Company Secretary & Compliance Officer), and Shruti Gupta (Additional Director). Each member contributes to the company's governance and operations.

As of March 2022, the management team of Desh Rakshak includes the following individuals:<BR><BR>1. Tosh Kumar Jain - Chairman & Managing Director<BR>2. Monika Jain - Whole-time Director<BR>3. Arihant Kumar Jain - Whole-time Director<BR>4. Mohit Kumar - Independent Director<BR>5. Sohini Bansal - Company Secretary & Compliance Officer<BR>6. Shruti Gupta - Additional Director<BR><BR>Each member plays a crucial role in the governance and operational management of the company.

View full answer

Who are the top shareholders of the Desh Rakshak?

17-Jul-2025

The top shareholders of Desh Rakshak include promoters, with Tosh Kumar Jain holding 28.2% of the shares, and individual investors owning 35.58%. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Desh Rakshak primarily include the promoters, with Tosh Kumar Jain holding the highest stake at 28.2%. Additionally, individual investors collectively own 35.58% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company, and there are no pledged promoter holdings.

View full answer

How big is Desh Rakshak?

24-Jul-2025

As of 24th July, Desh Rakshak Aushdhalaya Ltd has a market capitalization of 31.00 Cr, with recent Net Sales of 8.54 Cr and a Net Profit of 0.72 Cr. The company's Shareholder's Funds are 9.48 Cr and Total Assets amount to 16.32 Cr.

As of 24th July, Desh Rakshak Aushdhalaya Ltd has a market capitalization of 31.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 8.54 Cr and a Net Profit of 0.72 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 9.48 Cr and Total Assets of 16.32 Cr.

View full answer

How has been the historical performance of Desh Rakshak?

17-Nov-2025

Desh Rakshak's historical performance shows a mixed trend, with net sales increasing slightly to 6.27 Cr in Mar'25, stable operating profit, and improved profits before and after tax. Despite rising total liabilities, the company has demonstrated resilience with gradual improvements in profitability and sales.

Answer:<BR>The historical performance of Desh Rakshak shows a mixed trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Desh Rakshak's net sales have shown a slight increase from 6.01 Cr in Mar'24 to 6.27 Cr in Mar'25, following a peak of 6.60 Cr in Mar'21. The total operating income also reflects this trend, reaching 6.27 Cr in Mar'25. The total expenditure, excluding depreciation, increased from 4.73 Cr in Mar'24 to 5.02 Cr in Mar'25. Operating profit (PBDIT) has remained relatively stable, with a slight decrease from 1.30 Cr in Mar'24 to 1.28 Cr in Mar'25. Profit before tax improved from 0.51 Cr in Mar'24 to 0.56 Cr in Mar'25, while profit after tax rose from 0.43 Cr to 0.48 Cr in the same period. The earnings per share (EPS) increased from 0.97 in Mar'24 to 1.08 in Mar'25. On the balance sheet, total liabilities increased from 15.74 Cr in Mar'23 to 16.32 Cr in Mar'24, with total assets also rising to 16.32 Cr. The cash flow from operating activities showed a positive change, with 1.00 Cr reported in Mar'24, while cash flow from investing activities remained negative at -1.00 Cr in Mar'22 and Mar'21. Overall, Desh Rakshak has demonstrated resilience in its financial performance, with gradual improvements in profitability and sales despite fluctuations in expenses and liabilities.

View full answer

Is Desh Rakshak overvalued or undervalued?

24-Nov-2025

As of November 21, 2025, Desh Rakshak is fairly valued with a PE ratio of 37.17 and an EV to EBITDA of 14.92, showing strong performance compared to peers like Sun Pharma and Cipla, despite recent stock volatility and a YTD return of 159.81%.

As of 21 November 2025, Desh Rakshak's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued, with a PE ratio of 37.17, an EV to EBITDA of 14.92, and a Price to Book Value of 1.90. In comparison to its peers, Sun Pharma has a PE ratio of 36.98 and an EV to EBITDA of 24.43, while Cipla stands out as attractive with a PE ratio of 22.45 and an EV to EBITDA of 15.88.<BR><BR>Despite the recent volatility in its stock price, which has seen a significant YTD return of 159.81% compared to the Sensex's 9.08%, the company's valuation metrics suggest it is well-positioned within the pharmaceuticals and biotechnology sector. Overall, Desh Rakshak appears to be fairly valued in the current market environment.

View full answer

When is the next results date for Desh Rakshak Aushdhalaya Ltd?

11-Feb-2026

The next results date for Desh Rakshak Aushdhalaya Ltd is 13 February 2026.

The next results date for Desh Rakshak Aushdhalaya Ltd is scheduled for 13 February 2026.

View full answer

Are Desh Rakshak Aushdhalaya Ltd latest results good or bad?

14-Feb-2026

Desh Rakshak Aushdhalaya Ltd's latest results are poor, showing a 25.53% year-on-year decline in net sales and a 25% drop in net profit, despite a slight improvement in operating margins. The stock has also significantly decreased, trading down 71.72% from its 52-week high, indicating ongoing operational challenges.

Desh Rakshak Aushdhalaya Ltd's latest results indicate a challenging situation for the company. In Q3 FY26, the company reported net sales of ₹1.40 crores, which, while showing a sequential growth of 47.37% from the previous quarter, reflects a significant year-on-year decline of 25.53% compared to ₹1.88 crores in Q3 FY25. This pattern of revenue volatility raises concerns about the stability of demand and operational execution.<BR><BR>Net profit for the quarter was ₹0.09 crores, flat compared to the previous quarter but down 25% year-on-year. The operating margin improved to 17.86% from 15.43% a year ago, but this is a decline from 27.37% in the previous quarter, highlighting ongoing operational challenges.<BR><BR>Overall, the company's financial performance is characterized by declining revenues and profits, despite some improvements in margins. The stock has also faced significant pressure, trading down 71.72% from its 52-week high. Given these factors, the latest results can be considered poor, reflecting persistent operational headwinds and a lack of consistent growth.

View full answer

Should I buy, sell or hold Desh Rakshak Aushdhalaya Ltd?

24-Feb-2026

Why is Desh Rakshak Aushdhalaya Ltd falling/rising?

05-Mar-2026

As of 04-Mar, Desh Rakshak Aushdhalaya Ltd's stock price has fallen to Rs. 23.16, marking a new 52-week low and a decline of 4.97%. The stock has underperformed significantly over the past month and year, with a notable decrease in investor participation contributing to its bearish trend.

As of 04-Mar, Desh Rakshak Aushdhalaya Ltd's stock price is falling, currently at Rs. 23.16, which represents a decline of Rs. 1.21 or 4.97%. This drop is significant as it marks a new 52-week low for the stock. The performance today has underperformed the sector by 3.88%, and the stock opened with a loss of 4.97%. <BR><BR>In terms of recent trends, the stock has shown a negative return of 9.71% over the past week and a staggering 27.62% decline over the past month. Year-to-date, it has also fallen by 27.62%, while the broader market, represented by the Sensex, has only declined by 7.16% during the same period. The stock's performance over the last year is particularly concerning, with a return of -27.60%, contrasting sharply with the Sensex's gain of 8.39%.<BR><BR>Additionally, the stock is trading below its moving averages across various time frames, indicating a bearish trend. There has been a notable decrease in investor participation, with delivery volume dropping by 80% compared to the 5-day average. This lack of trading activity suggests waning interest among investors, further contributing to the stock's decline.<BR><BR>Overall, the combination of poor recent performance, low investor participation, and the stock hitting a new low are key factors driving the decline in Desh Rakshak Aushdhalaya Ltd's stock price.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 6.89%

  • Poor long term growth as Net Sales has grown by an annual rate of 7.89% and Operating profit at 9.58% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.92
2

Flat results in Dec 25

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 14 Cr (Micro Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

27

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.13

stock-summary
Return on Equity

4.88%

stock-summary
Price to Book

1.08

Revenue and Profits:
Net Sales:
1 Cr
(Quarterly Results - Dec 2025)
Net Profit:
0 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-34.2%
0%
-34.2%
6 Months
-71.4%
0%
-71.4%
1 Year
-27.6%
0%
-27.6%
2 Years
233.24%
0%
233.24%
3 Years
345.38%
0%
345.38%
4 Years
464.88%
0%
464.88%
5 Years
0%
0%
0.0%

Desh Rakshak for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Desh Rakshak Aushdhalaya Ltd Falls 9.74%: 3 Key Factors Driving the Decline

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Newspaper Publication

14-Feb-2026 | Source : BSE

The Company hereby submit Newspaper publication of Financial Results for the quarter and nine months ended December 31 2025

Board Meeting Outcome for Outcome Of Board Meeting Held On Friday 13Th Day Of February 2026 Meeting Commenced At 01:00 P.M. And Concluded At 02:00 P.M Pursuant To Para A Of Part A Of Schedule III And Regulation 30 Of The SEBI (LODR) Regulations 2015

13-Feb-2026 | Source : BSE

With reference to the captioned subject the company hereby inform that the Board of Directors of the Company in its meeting held on Friday 13th day of February 2026 has discussed considered and took noted and approved the following matters: 1.All the directors of the Company duly presented in the meeting and hence there was no leave of absence granted. 2.Took noted the minutes of the previous meeting of Board of Directors of the Company. 3. Considered and Approved the Un-Audited Financial Results for the quarter and nine months ended 31st day of December 2025. 4.Considered took noted and Approved the Limited Review Report on the financial results for the quarter and nine months ended 31st day of December 2025. 5.Took noted of the Closure of Trading window. 6.Considered took noted and Approved statement confirming that there is no deviation or variation in the use of the proceeds and the utilisation of fund.

Statement Of No Deviation(S) Or Variation(S) In The Use Of Proceeds And Utilization Of Funds Relating To Allotment Of Equity Shares On Preferential Basis Under Regulation 32 Of The SEBI (LODR) Regulations 2015

13-Feb-2026 | Source : BSE

Statement of no deviation or variation as per Regulation 32 of the SEBI (LODR) Regulations 2015

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
7.89%
EBIT Growth (5y)
9.58%
EBIT to Interest (avg)
0.92
Debt to EBITDA (avg)
2.49
Net Debt to Equity (avg)
0.13
Sales to Capital Employed (avg)
0.51
Tax Ratio
12.68%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.98%
ROE (avg)
5.02%

Valuation key factors

Factor
Value
P/E Ratio
21
Industry P/E
27
Price to Book Value
1.02
EV to EBIT
13.45
EV to EBITDA
8.68
EV to Capital Employed
1.02
EV to Sales
1.86
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.79%
ROE (Latest)
4.88%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Tosh Kumar Jain (21.93%)

Highest Public shareholder

Ruchika Chaturvedi (9.65%)

Individual Investors Holdings

49.84%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 47.37% vs -26.92% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 12.50% vs -20.00% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.40",
          "val2": "0.95",
          "chgp": "47.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.25",
          "val2": "0.26",
          "chgp": "-3.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.06",
          "val2": "0.08",
          "chgp": "-25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.09",
          "val2": "0.08",
          "chgp": "12.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "17.86%",
          "val2": "27.37%",
          "chgp": "-9.51%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is -0.88% vs 17.01% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -29.17% vs 84.62% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.25",
          "val2": "2.27",
          "chgp": "-0.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.50",
          "val2": "0.61",
          "chgp": "-18.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.13",
          "val2": "0.15",
          "chgp": "-13.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.17",
          "val2": "0.24",
          "chgp": "-29.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.22%",
          "val2": "26.87%",
          "chgp": "-4.65%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -12.05% vs 17.90% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -27.78% vs 38.46% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.65",
          "val2": "4.15",
          "chgp": "-12.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.75",
          "val2": "0.90",
          "chgp": "-16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.19",
          "val2": "0.23",
          "chgp": "-17.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.26",
          "val2": "0.36",
          "chgp": "-27.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.55%",
          "val2": "21.69%",
          "chgp": "-1.14%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 4.33% vs -2.75% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 11.63% vs 4.88% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.27",
          "val2": "6.01",
          "chgp": "4.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.25",
          "val2": "1.28",
          "chgp": "-2.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.36",
          "chgp": "-16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.48",
          "val2": "0.43",
          "chgp": "11.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "19.94%",
          "val2": "21.30%",
          "chgp": "-1.36%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
1.40
0.95
47.37%
Operating Profit (PBDIT) excl Other Income
0.25
0.26
-3.85%
Interest
0.06
0.08
-25.00%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.09
0.08
12.50%
Operating Profit Margin (Excl OI)
17.86%
27.37%
-9.51%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 47.37% vs -26.92% in Sep 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is 12.50% vs -20.00% in Sep 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
2.25
2.27
-0.88%
Operating Profit (PBDIT) excl Other Income
0.50
0.61
-18.03%
Interest
0.13
0.15
-13.33%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.17
0.24
-29.17%
Operating Profit Margin (Excl OI)
22.22%
26.87%
-4.65%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is -0.88% vs 17.01% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is -29.17% vs 84.62% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
3.65
4.15
-12.05%
Operating Profit (PBDIT) excl Other Income
0.75
0.90
-16.67%
Interest
0.19
0.23
-17.39%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.26
0.36
-27.78%
Operating Profit Margin (Excl OI)
20.55%
21.69%
-1.14%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is -12.05% vs 17.90% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is -27.78% vs 38.46% in Dec 2024

Annual Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
6.27
6.01
4.33%
Operating Profit (PBDIT) excl Other Income
1.25
1.28
-2.34%
Interest
0.30
0.36
-16.67%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.48
0.43
11.63%
Operating Profit Margin (Excl OI)
19.94%
21.30%
-1.36%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 4.33% vs -2.75% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is 11.63% vs 4.88% in Mar 2024

stock-summaryCompany CV
About Desh Rakshak Aushdhalaya Ltd stock-summary
stock-summary
Desh Rakshak Aushdhalaya Ltd
Micro Cap
Pharmaceuticals & Biotechnology
The flagship company Desh Rakshak Aushdhalaya Limited of Bhagwant Group was originally started in 1901 as a proprietoryship Concern by late Shri Bhagwant Rai Jain, a well renowned Vaidya Father of Late Dr. Paras Kumar Jain, Ex Chairman & Managing Director of the Company. The Concern was converted into a Private Limited Company in Jul.'94. Desh Rakshakare the oldest manufacturer of Pure Ayurvedic and Herbal Products as discovered by the Ancient Seers & Sages.
Company Coordinates stock-summary
Company Details
Bhagwant Kuti, Kankhal Haridwar UTT : 249408
stock-summary
Tel: 91-1334-243833
stock-summary
daral96@yahoo.in/dral95@yahoo.com
Registrar Details
MAS Services Ltd, T-34 , 2nd Floor, Okhla Industrial Area, Phase - II, New Delhi